US 12,473,359 B2
Chimeric antigen receptors targeting CD-19
James N. Kochenderfer, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,249.
Application 17/696,249 is a continuation of application No. 17/557,845, filed on Dec. 21, 2021.
Application 17/557,845 is a continuation of application No. 16/360,281, filed on Mar. 21, 2019, granted, now 11,236,161, issued on Feb. 1, 2022.
Application 16/360,281 is a continuation of application No. 15/315,533, granted, now 10,287,350, issued on May 14, 2019, previously published as PCT/US2015/033473, filed on Jun. 1, 2015.
Claims priority of provisional application 62/006,313, filed on Jun. 2, 2014.
Prior Publication US 2022/0204619 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 16/2803 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70535 (2013.01); C07K 14/70578 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); A61K 2239/13 (2023.05); A61K 2239/31 (2023.05); A61K 2239/48 (2023.05); C07K 2317/21 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01)] 44 Claims
 
1. A chimeric antigen receptor (CAR) directed against CD19, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 1.